Patent · US Active

Method for diagnosing a rhinovirus infection

US9638694B2 · kind B2 · utility

1Cited by

0References

5Claims

0Family size

Assignee

Viravaxx AG · AT

Inventors

Rudolf Valenta · Theresienfeld, AT
Katarzyna Niespodziana · Wien, AT
Johanna Edlmayr · Munich, DE
Dieter Blaas · Wien, AT
Verena Niederberger-Leppin · Wien, AT
Nikos Papadopoulos · Erythres, GR
Theresia Popow-Kraupp · Wien, AT

Key dates

Filing date	Nov 2, 2010
Grant date	May 2, 2017
Priority date	—
Expiry date	Dec 18, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2469/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.